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Individualized drug dosage in patients treated with continuous to continuous hemofiltration follow a general rule, much
hemofiltration. more so than during intermittent hemodialysis. This
Background. Subtherapeutic drug dosing may be even more gives reason for basing drug dosage on the easy-to-mea-dangerous than overdosage, especially for intensive care pa-
sure total serum creatinine clearance (CCr).tients requiring hemofiltration.
Proposal. According to Dettli’s fundamental equation, body
clearance of any drug (Cl) is a linear function of creatinine
THEORETICAL CONCEPTclearance (Cl 5 Cl anur 1 a · CCr), with [a 5 (Cl norm 2
Cl anur)/CCr norm]. We propose to individualize drug dosage According to Dettli’s fundamental equation [4], drug
during high-flux hemofiltration by basing it on Dettli’s equation clearance (Cl) is a linear function of CCr. Nonrenal drugand on total CCr (CCr tot 5 CCr ren 1 CCr filt). Using this clearance values in healthy volunteers can even be usedapproach, drug clearance will eventually be overestimated for
to predict drug clearance for functionally anuric patientsdrugs with substantial tubular secretion and for high-efficiency
hemofiltration (CCr tot . 30 ml/min). (Cl nonren > CL anur).
Conclusion. In patients undergoing hemofiltration, the total
Cl 5 Cl anur 1 a · CCrCCr approach might be a practical alternative to standardized
dosing schemes for deriving an individualized dosage from
This dependence has been investigated in patients andpublished pharmacokinetic data and functions.
confirmed for many drugs. Thus, the following holds [a 5
(Cl norm 2 Cl anur)/CCr norm].
The Dettli equation can even be applied to hemofil-In renal impairment, dosage reduction is recom-
tration circumstances by introducing the total CCr conceptmended for more than one half of all drugs available.
(CCr tot). Although for continuous hemofiltration, renalUnderdosage of drugs can be even more dangerous than
CCr (CCr ren) adds up with the extracorporeal CCr (CCr filt)overdosage, especially for anti-infective therapy in criti-
to form the total CCr (CCr tot 5 CCr ren 1 CCr filt).cally ill patients. Therapeutic drug-level monitoring very
often is available only post hoc, if at all. Hemofiltration CCr tot 5
experts usually propose to derive drug dosage adjust-
ments from unbound free plasma fraction, or sieving (CreaFiltrate · VolumeFiltrate) 1 (CreaUrine · VolumeUrine)
SCr · 1440
[ml/min]
coefficient [1]. However, adsorption by the membrane
could substantially contribute to drug elimination [2]. At least as a rule of thumb, the 1/Crea method might
The sieving coefficient might be influenced by alterations be used; a serum creatinine of 200 mmol/liter indicates
in drug protein binding [3]. In addition, this approach 50% renal impairment [1/Crea > glomerular filtration
does not take into account spontaneous renal function rate (GFR) percentage].
and actual clinical situation.
Hemofiltration is by no means a standardized proce-
DISCUSSIONdure. The blood flow rate is 50 to 200 ml/min, and the
substitution volume ranges from 500 to 3000 ml per hour, In patients on continuous hemofiltration, serum creati-
with or without a combination of dialysate flow. On the nine should not be higher than 200 to 400 mmol/liter,
other hand, the pharmacokinetic principles that apply requiring ultrafiltration rates between 500 and 3000 ml/hr.
Accordingly, the total CCr is to be estimated between 10
and 50 ml/min [5]. This compares with weekly averagedKey words: intensive care, high-flux hemofiltration, creatinine clear-
ance, drug monitoring. values for the CCr of only 5 to 10 ml/min by intermittent
hemodialysis. Likewise, the usual dose reductions that 1999 by the International Society of Nephrology
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Fig. 1. Drug clearance as a function of creati-
nine clearance. Fundamental pharmacoki-
netic principles (A) can be applied to the con-
dition of continuous hemofiltration (B). The
additional line in the right-hand diagram rep-
resents the general effect of hemofiltration on
drug clearance (Cl 5 Cl anur 1 CCr tot). Two
extreme examples are illustrated: (a) The ac-
tual effect of hemofiltration on drug clearance
might be overestimated for drugs with a high
tubular secretion rate (for example, b-lactam
antibiotics), and (b) the effect of hemofiltra-
tion is underestimated for drugs for which con-
siderable tubular reabsorption takes place (for
example, amino acids and vitamin C).
are standardized to intermittent hemodialysis could lead (Tm), Michaelis-constant (Km), and the concentration
to an inefficiently low dosage in continuous hemofiltra- in plasma (C). The clearance by secretion is a function
tion. For meropenem, vancomycin, fluconazole, imipe- of GFR because it can occur only into the tubular lumen
nem, cefepime, and piperacillin, it has been shown that containing the glomerular ultrafiltrate. The following
an almost normal dosage is needed in patients on hemo- equations are generally accepted: (Tm 5 const.) and
filtration [1, 6–9]. (Km 5 const.). The concentration (C) could increase,
The total CCr approach can be applied to the hemofil- however, if renal function is impaired; in the most simple
tration situation because high-flux hemofiltration is simi- case, there is a reciprocal proportionality (b) to the CCr
lar to natural glomerular filtration. Glomerular drug fil- (C 5 b/CCr). In this case, drug clearance depends on CCr
tration depends on unbound fraction in plasma (fu) and according to a nonlinear function. By transformation, it
glomerular filtration rate, where (CCr > GFR). can be shown that a quadratic function holds for the
dependence of drug clearance on CCr [4].Cl filt 5 fu · CCr
Cl 5 Cl anur 1 fu · CCr 1 [Tm/(b 1 Km · CCr)] · CCr2The metabolic capacity of the kidneys has long been
overlooked [10]. Metabolic clearance as in the case of For theoretical reasons, the nonlinear function for drug
insulin takes place right after glomerular filtration. By clearance, including tubular secretion and the depen-
taking into account this effect, renal drug clearance is dence on CCr, is left bent and convex, but it is never rightassessed more accurately from CCr than from the urinary bent or concave.
drug excretion rate.
b-Lactam antibiotics, especially penicillins, are also
Any clearance, however, will be estimated too high for eliminated by tubular secretion. If the published correla-
deteriorating renal function and too low in the restitution
tions between drug clearance and CCr are extrapolatedphase of renal failure. If continuous hemodialysis is used
to the effect of hemofiltration, an overestimation of druginstead of or in addition to hemofiltration, total CCr can clearance results. Because of the convex correlation, theoverestimate drug clearance, depending on molecular
error is low in the case of low CCr (Fig. 1). On the othersize. The total CCr approach furthermore has two limita- hand, creatinine is also eliminated by tubular secretion;tions (Fig. 1). Hemofiltration does not provide clearance
thus, CCr generally overestimates glomerular filtration.by tubular secretion nor does tubular reabsorption take
These two errors balance, and the wrong dosage willplace resulting in the general equation for drug clearance
most likely not prove clinically disastrous.during hemofiltration.
In addition, intestinal secretion of drugs can compen-
Cl 5 Cl anur 1 CCr tot sate for missing tubular secretion. The so-called Lauter-
bach effect partly minimizes the error of overestimationIf dosage is adjusted according to total CCr, an overdos-
of the hemofiltration effect. Compensatory intestinal se-age can result, especially with drugs largely eliminated
cretion (exsorption) has been shown for imipenem orby tubular secretion and in patients with near-normal
quinolones in renal failure [11, 12].serum creatinine values.
Underestimation in the case of tubular reabsorptionOverestimation in the case of tubular secretion
Tubular reabsorption operates in only very few drugs.Tubular secretion by nonspecific transporters plays
It has been shown that elimination of amino acids oran important role in cationic and anionic drugs. The
vitamin C by hemofiltration is higher than by normalclearance by tubular secretion adds to glomerular filtra-
tion. Tubular secretion depends on transport maximum renal function [13, 14]. Because hemofiltration does not
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